Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
Australian Institute for Suicide Research and Prevention, National Centre of Excellence in Suicide Prevention, WHO Collaborating Centre for Research and Training in Suicide Prevention, Mt Gravatt Campus, Griffith University, Queensland, Australia a.degioannis@griffith.edu.au.
Angelo
A
De Gioannis
Australian Institute for Suicide Research and Prevention, National Centre of Excellence in Suicide Prevention, WHO Collaborating Centre for Research and Training in Suicide Prevention, Mt Gravatt Campus, Griffith University, Queensland, Australia.
Diego
D
De Leo
D000284:Administration, Oral; D000328:Adult; D000778:Anesthetics, Dissociative / Q000008:administration & dosage / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D061218:Depressive Disorder, Treatment-Resistant / Q000188:drug therapy* / Q000523:psychology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007649:Ketamine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D059020:Suicidal Ideation
D000778:Anesthetics, Dissociative; D000928:Antidepressive Agents; D007649:Ketamine